Treatment progress of follicular lymphoma
10.3760/cma.j.cn115356-20240124-00014
- VernacularTitle:滤泡淋巴瘤治疗进展
- Author:
Zhijuan LIN
1
;
Bing XU
Author Information
1. 厦门大学附属第一医院血液科 厦门大学血液病学系 厦门市血液病质控中心 厦门市血液治疗精准诊治重点实验室，厦门 361003
- Keywords:
Lymphoma, follicular;
Recurrence;
Refractory;
American Society of Hematology;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2024;33(3):138-141
- CountryChina
- Language:Chinese
-
Abstract:
Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. The 2023 American Society of Hematology (ASH) annual meeting announced the latest updates on newly diagnosed and relapsed/refractory FL, including the targeted therapy, bio-specific antibodies and chimeric antigen receptor T-cell (CAR-T) therapy. This review provides an overview of these updates.
